Skip to content
DE

TrofinetidePrescription medicine

Trofinetide is a small molecule derived from a peptide fragment associated with IGF-1. It has been studied for the everyday symptoms of Rett syndrome, a rare neurodevelopmental condition.

What is Trofinetide?

Trofinetide is a small peptide-derived compound investigated for symptoms of Rett syndrome, a rare neurodevelopmental condition. It is related to the glycine-proline-glutamate fragment of IGF-1.

How it works

Proposed actions involve nerve-cell communication and inflammatory signalling. The precise mechanism responsible for clinical effects is not fully established.

Effects studied

Rett-related symptoms and overall clinical change

The twelve-week LAVENDER trial compared trofinetide with placebo using caregiver assessments of Rett-related behaviours and a clinician rating of overall improvement. These symptom outcomes do not establish a cure or repaired nerve connections. 1

Evidence: Randomised placebo-controlled Rett syndrome trial

What does the evidence show?

The retained LAVENDER paper is a randomised trial using caregiver and clinician assessments. Its findings apply to Rett syndrome and cannot be treated as evidence for general cognitive enhancement.

A treatment with a specific question

Rett syndrome affects communication, movement and other functions, often after an early period of apparently typical development. Trofinetide is related to glycine-proline-glutamate, a fragment of insulin-like growth factor 1. The relationship gives researchers a biological lead; it does not mean the drug simply replaces a missing hormone.

How benefit was assessed

LAVENDER compared trofinetide with placebo over twelve weeks. Caregivers assessed changes in Rett-related behaviours, and clinicians rated overall improvement. These measures capture meaningful clinical perspectives, but do not directly show repaired nerve connections or a cure. Interpretation remains limited to the study population and duration. 1

The mechanism remains less settled

Laboratory explanations concern nerve-cell communication and inflammatory signalling, but the precise mechanism behind a clinical response remains uncertain. A trial can still measure benefit without fully explaining how it occurs. Those are separate research questions.

Tolerability is part of the result

Diarrhoea and vomiting can make treatment demanding. Hydration, food intake and weight therefore matter alongside symptom scores. A short trial cannot settle all questions about long-term benefit or burden. The separate predecessor-programme page explains why earlier work in other conditions should not be merged with the Rett evidence. 2

Safety & status

Diarrhoea and vomiting can create a substantial treatment burden. Hydration, food intake and weight matter alongside symptom assessments. 2

Country and product status

This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.

Frequently asked questions

Does it replace IGF-1?

No. Its relationship to an IGF-1-derived fragment does not make it hormone replacement.

Can Rett syndrome results be applied to general cognition?

No. The population and measured symptoms are specific; work in other conditions needs a separate assessment.

Further reading

Concept illustration for Trofinetide.GuideTrofinetide: treating Rett syndrome, and its side effectsWhat the pivotal trial of trofinetide showed, how the drug is used and which gastrointestinal risks matter most.Read the article

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. Trofinetide: paper 10.1038/s41591-023-02398-1 Research reference · Retained archive reference; not independently checked for this draft.
  2. Trofinetide: www.accessdata.fda.gov reference Reference or product information · Retained archive reference; not independently checked for this draft.
  3. Trofinetide: dailymed.nlm.nih.gov reference Reference or product information · Retained archive reference; not independently checked for this draft.
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.